Kevin V. Sullivan
Direktor/Vorstandsmitglied bei Qing Bile Therapeutics, Inc.
Aktive Positionen von Kevin V. Sullivan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Qing Bile Therapeutics, Inc. | Direktor/Vorstandsmitglied | 01.05.2015 | - |
Karriereverlauf von Kevin V. Sullivan
Ehemalige bekannte Positionen von Kevin V. Sullivan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
APPILI THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.06.2015 | 02.12.2019 |
Vorstandsvorsitzender | 07.05.2015 | 02.12.2019 | |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Vorstandsvorsitzender | 01.05.2013 | 01.04.2015 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Geschäftsführer | 21.05.2012 | 01.05.2013 |
Corporate Officer/Principal | 01.01.2003 | 21.05.2012 |
Ausbildung von Kevin V. Sullivan
Richard Ivey School of Business | Masters Business Admin |
Statistik
International
Kanada | 6 |
Operativ
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
APPILI THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |
Qing Bile Therapeutics, Inc. |
- Börse
- Insiders
- Kevin V. Sullivan
- Erfahrung